The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: The Veterans Affairs Diabetes Trial previously showed that intensive glucose lowering, as compared with standard therapy, did not significantly reduce the rate of major cardiovascular events among 1791 military veterans (median follow-up, 5.6 years). We report the extended follow-up of the study participants. METHODS: After the conclusion of the clinical trial, we followed participants, using central databases to identify procedures, hospitalizations, and deaths (complete cohort, with follow-up data for 92.4% of participants). Most participants agreed to additional data collection by means of annual surveys and periodic chart reviews (survey cohort, with 77.7% follow-up). The primary outcome was the time to the first major cardiovascular event (heart attack, stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, or cardiovascular-related death). Secondary outcomes were cardiovascular mortality and all-cause mortality. RESULTS: The difference in glycated hemoglobin levels between the intensive-therapy group and the standard-therapy group averaged 1.5 percentage points during the trial (median level, 6.9% vs. 8.4%) and declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a median follow-up of 9.8 years, the intensive-therapy group had a significantly lower risk of the primary outcome than did the standard-therapy group (hazard ratio, 0.83; 95% confidence interval [CI], 0.70 to 0.99; P=0.04), with an absolute reduction in risk of 8.6 major cardiovascular events per 1000 person-years, but did not have reduced cardiovascular mortality (hazard ratio, 0.88; 95% CI, 0.64 to 1.20; P=0.42). No reduction in total mortality was evident (hazard ratio in the intensive-therapy group, 1.05; 95% CI, 0.89 to 1.25; P=0.54; median follow-up, 11.8 years). CONCLUSIONS: After nearly 10 years of follow-up, patients with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had 8.6 fewer major cardiovascular events per 1000 person-years than those assigned to standard therapy, but no improvement was seen in the rate of overall survival. (Funded by the VA Cooperative Studies Program and others; VADT ClinicalTrials.gov number, NCT00032487.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Post-trial observational follow-up of the VADT over 10 years has also shown a significant reduction in the primary outcome of major CVD events, with myocardial infarctions and heart failure being the most common outcomes (60).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [60]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, during an observational median follow up of 9.8 years, the intensive-therapy group had a significantly lower risk of the primary outcome (MI, stroke, new or worsening congestive heart failure [CHF], amputation for ischemic gangrene, or CV-related death) than did the standard therapy group (HR 0.83, p=0.04), with an absolute reduction in risk of 8.6 major CV events per 1,000 personyears (”
From Targets for Glycemic Control (2018) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, longer-term epidemiological follow-up of these studies also showed a pattern of CVD benefit (58-60).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [60]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In people with type 2 diabetes and established, or very high risk for, cardiovascular disease (CVD), there is a clear association between an increased mortality and severe hypoglycemia (62,63) and symptomatic hypoglycemia (64).”
From Hypoglycemia (2018) · cites this paper as [62]
Experimental — accuracy not yet measured
In the citing paper
“Meta-analyses have clearly shown that tight blood glucose control leads to the suppression of ASCVD incidence795, 796).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [795]
In the citing paper
“However, 10-year follow-up of the VADT cohort (64) did demonstrate a reduction in the risk of cardiovascular events (52.7 [control group] vs. 44.1 [intervention group] events per 1,000 person-years) with no benefit in cardiovascular or overall mortality.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
In the citing paper
“However, 10-year follow-up of the VADT cohort (64) did demonstrate a reduction in the risk of cardiovascular events (52.7 [control group] vs. 44.1 [intervention group] events per 1,000 person-years) with no benefit in cardiovascular or overall mortality.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
In the citing paper
“However, 10-year follow-up of the VADT cohort (64) did demonstrate a reduction in the risk of cardiovascular events (52.7 [control group] vs. 44.1 [intervention group] events per 1,000 person-years) with no benefit in cardiovascular or overall mortality.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
In the citing paper
“In all three trials, severe hypoglycemia was significantly more likely in participants who were randomly assigned to the intensive glycemic control arm.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Self-citationMeta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Flagged first, then by citations
Research works printed but not linked: 1
- Hayward RA, 2007, Am J Manag Care, 13, 126
Cited by
Sorted by citations
Items 601–667 of 667
Novel clinico-molecular insights into the role of bisphenol-A (BPA) in the etiology of diabetes
Soundararajan, A. (2019) · Own your potential (DEAKIN)
Screening for atrial fibrillation and treatment with anticoagulant to prevent stroke
Ghazal, F. (2020) · Figshare
Zhang, Y., Hu, Y., Ho, K., Hartzel, D. N., Abedi, V., Zand, R., Williams, M. S., & Lee, M. T. M. (2020) · medRxiv · doi:10.1101/2020.03.18.20037218
Atherogenic dyslipidemia typical for metabolic syndrome
Blaha, V., Víšek, J., & Lášticová, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.003
“typu má pro ovlivnění rizika aterosklerotického kardiovaskulárního onemocnění jen omezený význam (3).”
BackgroundMuñoz, C. A. V., & Romero, M. (2019) · Revista de investigación universitaria en salud. · doi:10.56487/x5f1g555
Sheryazdanova, D. N., Laryushina, Y., Muravlyova, L., Turgunova, L., Alina, A., Vassilyeva, N., & Turmukhambetova, A. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.4674
“According to such iconic studies as UKPDS and VADT, the glucose reduction is associated with a lower number of cardiovascular events and mortality in type 2 diabetes [32], [33], [34].”
BackgroundHow can older adults combat diabetes to achieve a longer and healthier life
Shang, Y. (2021) · Figshare
Pharmacist Impact on Physician Practices Related to Diabetes Management
Ammar, A., Darghali, L. M., Tarraf, W., Berlie, H. D., & Jaber, L. A. (2021) · Advances in Social Sciences Research Journal · doi:10.14738/assrj.84.10081
Discordance between fasting plasma glucose and A1c in the diagnosis and management of diabetes
Sarinnapakorn, V., Deerochanawong, C., Niramitmahapanya, S., Napartivaumnuay, N., & Treesaranuwattana, T. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.12.1.0521 · Cited by 1
“Both FPG and A1c are beneficial in diagnosing diabetes [2,3] and in monitoring glycemic control [4], and A1c levels can often indicate chronic complications from diabetes [5,6,7,8,9,10,11,12,13]; however, there are often problems with discordance between FPG and A1c.”
BackgroundAfridi, M. H., Khan, M. N., Khan, A. M., Abbass, M., Ikram, Q., Hassan, J., Bibi, K., & Zaib, S. (2022) · American Journal of Health Medicine and Nursing Practice · doi:10.47672/ajhmn.916
(2021) · Elsevier eBooks · doi:10.1016/b978-3-437-22931-2.00038-4
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_14
Glandt, M., & Bloomgarden, Z. T. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_48-1
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_44
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-2
Glandt, M., & Bloomgarden, Z. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_48
Treating Type 2 Diabetes Mellitus
Migdal, A. L., & Abrahamson, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-1
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
Diabetes Medications and Cardiovascular Disease Prevention
Rho, J., Lee, Y.-A., Song, S.-W., & Kang, S.-G. (2022) · Korean Journal of Family Practice · doi:10.21215/kjfp.2022.12.2.61
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735910698.793566214
(2015) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2015.8.0342
Antoku, Y., Takemoto, M., Mito, T., Shiiyama, R., Otsuka-Morisaki, H., Tanaka, A., Maeda, Y., & Tsuchihashi, T. (2020) · doi:10.21203/rs.3.rs-16651/v1
Désordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00009-9
Fernández-Gárate, J. E., Manuel‐Apolinar, L., Zurita‐Cruz, J. N., Acevedo, M. D. L. B., Arellano-Flores, M. L., González, R. A. C., & González, N. C. (2020) · doi:10.21203/rs.2.20136/v1
“Evidence regarding the effects of primary care on various health outcomes, corresponding hospitalizations or death has been documented in different studies, some of which evaluated the impact of specific programs [6-10]; other studies have analyzed hospitalization trends for potentially preventable chronic conditions,…”
ResultSecondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit
Egers, M. I., & Hynes, M. (2022) · Journal of Kidney Care · doi:10.12968/jokc.2022.7.5.216
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Paradigm sift of the medical care in diabetes
Okajima, F. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.32
Look in or book in: The case for type 2 diabetes remission to prevent diabetic retinopathy
Cripps, J., & Cucuzzella, M. T. (2023) · Journal of Metabolic Health · doi:10.4102/jir.v6i1.79
“56,57,58,59,60,61 These consistent findings from highly funded and well-conducted trials make the case for an alternative approach to treating people with T2D with a focus on addressing insulin resistance.”
Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
Peter, P. R., & Inzucchi, S. E. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_37
Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes
Jenkins, A. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_29
Cywes, R., Kajee, H., Wellington, N., Cucuzzella, M. T., Riley, K., Isaacs, D. M., Pataguana, N., Lake, I., Rauch, L., McKelvey, S., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821617-0.00010-3
LIVE INDIA: Effectiveness of Gla-100 in a Post hoc Pooled Analysis of FINE ASIA and GOAL Registries
Deshmukh, V. C., Chaudhury, T., Chadha, M. D., Chawla, M. S., Mukherjee, S., Pitale, S., Basu, D., Gadekar, A. V., MENON, S. K., Trivedi, C. A., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01469-3
“In both studies, people on intensive treatment attained lower glycated hemoglobin (HbA1c) values and had lower risk of developing both micro-and macro-vascular complications [5, 6].”
Gil, F. M. A. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.proteccionholistica.art3
León, J. S. T., Ardila, L. J. P., Santamaria, M. J. C., Quintero, V. Q., Campo, E. R. Z., Corzo, M. J. O., Cantillo, F. A. A., Romero, L. D. J., Medina, R. A. A., Solano, M. J. C., et al. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i1.10179
“…el mismo efecto legado: el Ensayo de Diabetes de Asuntos de Veteranos (VADT) realizado en pacientes diabéticos tipo 2 de larga evolución (11, 12, 13), el ensayo Acción para Controlar el Riesgo Cardiovascular en la Diabetes (ACCORD) con más de 10 000 pacientes diabéticos tipo 2 de larga…”
Pallarés‐Carratalá, V., Ruiz‐García, A., Serrano-Cumplido, A., Segura‐Fragoso, A., Fernández-Pascual, V., Sánchez-Sánchez, B., Cervera-Pérez, M. I., Alonso-Moreno, F. J., Arranz-Martínez, E., Barquilla-García, A., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.arteri.2024.05.001
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21035-8.00039-2
Chiavaroli, L., Mirrahimi, A., Ireland, C., Mitchell, S. A., Sahye‐Pudaruth, S., Coveney, J., Olowoyeye, O. A., Maraj, T., Patel, D. K., de Souza, R. J., et al. (2024) · doi:10.32920/26521318
Chiavaroli, L., Mirrahimi, A., Ireland, C., Mitchell, S. A., Sahye‐Pudaruth, S., Coveney, J., Olowoyeye, O. A., Maraj, T., Patel, D. K., de Souza, R. J., et al. (2024) · doi:10.32920/26521318.v1
Arumugam, A., & Rajesham, V. V. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i3.53818
ASSESSMENT OF THE FREQUENCY OF RISK FACTORS FOR CARBOHYDRATE METABOLISM DISORDERS
Yusupova, S., Mukhamedova, V., & Matkarimova, M. (2025) · Medical science of Uzbekistan · doi:10.56121/2181-3612-2025-2-18-20
Tan, J., Lim, G. H., Tan, H. Y., Sng, G. G. R., Thumboo, J., & Mong, B. Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5236698
Optimizing polypharmacy in elderly with diabetes through routine benefit–risk assessment
AL‐Musawe, L., Ismael, A. H., & Al-Mukhtar, E. J. (2024) · Aging Research · doi:10.26599/agr.2025.9340038
Early glycemic control and subsequent risk of incident dementia among new metformin users
Power, M. C., Madsen, M., Bødkergaard, K., Zimmerman, S. C., Ackley, S. F., Gilsanz, P., Glymour, M. M., Henderson, V. W., Sørensen, H. T., & Thomsen, R. W. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.10.017 · Cited by 4
Jayaraman, S., Choi, K., Pérez, A., Miñambres, I., Sánchez‐Quesada, J. L., & Gursky, O. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168142
Urina-Jassir, M., Herrera-Parra, L. J., Hernández Vargas, J. A., Valbuena-García, A. M., Acuña-Merchán, L., & Urina-Triana, M. (2021) · Figshare · doi:10.6084/m9.figshare.14853189
Pei, J., Wang, X., Pei, Z., & Hu, X. (2023) · Figshare · doi:10.6084/m9.figshare.24452462
Zhou, Z., Liu, Q., Zheng, M., Zuo, Z., Zhang, G., Shi, R., & Wu, T. (2024) · Figshare · doi:10.6084/m9.figshare.26074138
Gumprecht, J., Lip, G. Y. H., Sokal, A., Średniawa, B., Stokwiszewski, J., Zdrojewski, T., Rutkowski, M., Grodzicki, T., Kaźmierczak, J., Opolski, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2517000/v1
Choi, I. J., Choo, E. H., Kim, H. J., Lim, S., Moon, D., Lee, K. Y., Hwang, B.-H., Kim, C. J., Park, M.-W., Lee, J.-M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17210668
Urina-Jassir, M., Herrera-Parra, L. J., Hernández Vargas, J. A., Valbuena-García, A. M., Acuña-Merchán, L., & Urina-Triana, M. (2021) · Figshare · doi:10.6084/m9.figshare.14853186
Diabetes educational interventions in care homes: a scoping review
Walker, K.-A., Craig, S. G., Anderson, T., Stark, P., Wilson, C. B., Carter, G., McEvoy, C. T., Creighton, L., Henderson, E., Porter, S., et al. (2026) · BMC Medical Education · doi:10.1186/s12909-026-08738-2
“Proper management of diabetes in these environments is critical [26–28] as poor glycaemic control can lead to significant complications [29]– [30], including hypoglycaemia [31], cardiovascular issues [32], and impaired wound healing [33].”
Duman, J. M. E. (2026) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub1266.c5158
Influence du genre sur la prise en charge des patients diabétiques âgés en soins primaires
Al‐Salameh, A. (2018) · theses.fr (ABES) · doi:10.70675/217d4ac1z2675z4cfaz8123z5c7f1162be47
Hawash, M., Çapan, İ., Henawi, H., Jawabre, B., Nassif, Y., Zorba, I., Kamiński, M. D., Góral, T., Sutula, S. M., Dominiak, P. M., et al. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146300
Les traitements du diabète de type 2 : les preuves
Bordier, L., & Bauduceau, B. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100822
Tang, Y.-T., Wu, Q., Chen, Y., Xia, L., Yang, M. H., Wei, M.-Y., Pang, Q., Yang, Y.-N., Liu, J.-B., Liu, J.-L., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.120448
Shikata, K., Miyamoto, S., Haneda, M., Hosoi, H., Sakamoto, K., Suzuki, Y., Suzuki, D., Ishida, H., Akai, H., Tomino, Y., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70392
“This fi nding may partly be explained by a legacy effect, as reported in clinical trials involving participants with earlier stages of diabetes 10, 12, 13 .”
Adapting Global Diabetes Management Guidelines for Low Resource Settings
Baayou, M. (2026) · مجلة البحوث الأكاديمية · doi:10.65540/jar.v30i.1595
Ahmed, S., McCollin, S. P., Martí-Carvajal, A. J., Akus, M., Baron, D. W., Razzaq, S. A., Scudder, P. N., Honigsberg, E. J., Nasir, S., Peng, K., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016380
Aihara, M., & Kubota, N. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70447
“…behavior changes Tight glycemia control reduces the risk of complications in people with diabetes, but the bene fi t is preventive and often distant: the macrovascular payoff may take years to emerge 102 and mixed results are obtained even with intensi fi ed multifactorial intervention 145 .”
鈴木, 奈., Ooba, N., Nakajima, R., Takabatake, K., Saita, M., Kawakami, E., Kawana, M., Watanabe, D., & Hashiba, H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0359960
“Diabetes represents a major risk factor for microvascular and macrovascular complications [3], making effective glycemic management essential to reduce these risks [4,5].”
Janram, A., Chanajarunwit, O., Anothaisintawee, T., Yang, J., Looareesuwan, P., Siriyotha, S., & Thakkinstian, A. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-119475
“10 11 Therefore, achieving diabetes remission is expected to lower the risk of these complications.”
Untitled work
Diabetes Canada Clinical Practice Guidelines Expert Committee (n.d.) · Diabetes Canada
Metadata
- Authors
- Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V.
- Affiliations
- Edward Hines, Jr. VA Hospital (US)
- Phoenix VA Health Care System (US)
- VA Ann Arbor Healthcare System (US)
- Veterans Health Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-04
- Volume
- 372
- Issue
- 23
- Pages
- 2197-2206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153552938
- Cited by
- 668
- References
- 27
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 30 · 2023: 47 · 2022: 28 · 2021: 53 · 2020: 60 · 2019: 77 · 2018: 73 · 2017: 105 · 2016: 113 · 2015: 44
- FWCI
- 97.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (98‐004)
- Amgen
- AstraZeneca
- Health Services Research and Development
- Novo Nordisk
- National Institutes of Health (98-004)
- National Heart, Lung, and Blood Institute (R01HL067690, R01HL094775)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, HbA1c, major cardiovascular events, cardiovascular mortality, all-cause mortality, military veterans, long-term follow-up, cardiovascular risk reduction, congestive heart failure, amputation, stroke, myocardial infarction, ischemic gangrene
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
